Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

Blood Neoplasia. 2025 Apr 3;2(3):100096. doi: 10.1016/j.bneo.2025.100096. eCollection 2025 Aug.

Emil Ramsø Kyvsgaard^{1

2

3

4}, Trine Lønbo Grantzau⁵, Mia Dahl Sørensen^{6

7}, Michael Boe Møller^{6

7}, Lene Dissing Sjø⁵, Morten Grauslund⁵, Trine Trab^{1

2}, Linea Cecilie Melchior⁵, Lærke Sloth Andersen¹, Caroline Riley^{1

3}, Carsten U Niemann^{1

8}, Jacob Haaber⁹, Thomas Stauffer Larsen⁹, Michael Roost Clausen¹⁰, Kirsten Grønbæk^{1

2

8}, Martin Hutchings^{1

3

8}, Simon Husby^{1

2

3}

¹ Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
² Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark.
³ Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
⁴ Department of Internal Medicine, Aalborg University Hospital Thisted, Thisted, Denmark.
⁵ Department of Pathology, Rigshospitalet, Copenhagen, Denmark.
⁶ Department of Pathology, Odense University Hospital, Odense, Denmark.
⁷ Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁸ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
⁹ Department of Hematology, Odense University Hospital, Odense, Denmark.
¹⁰ Department of Hematology, Vejle Sygehus, Vejle, Denmark.

No abstract available